Lung Cancer Clinical Trial
Official title:
Phase II Quality of Life Study of Stereotactic RadioSurgery, Temozolomide and Erlotinib Chemotherapy for the Treatment of 1-3 Brain Metastases in Non-small Cell Lung Cancer
RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain
function (the ability to think, learn, remember, and judge) in patients with non-small cell
lung cancer and brain metastases. A study that evaluates brain function may help doctors
plan the best treatment.
PURPOSE: This phase II trial is studying the effect of radiosurgery, temozolomide, and
erlotinib on brain function in patients with non-small cell lung cancer and brain
metastases.
OBJECTIVES:
Primary
- Determine the effect of stereotactic radiosurgery, temozolomide, and erlotinib
hydrochloride on cognitive function in patients with non-small cell lung cancer and
brain metastases.
Secondary
- Determine the feasibility and safety of this regimen, in terms of tumor response, time
to tumor progression in brain, survival, physical functioning, and quality of life, in
these patients.
- Determine the frequency of O6-methylguanine-DNA methyltransferase promoter methylation
in these patients.
OUTLINE: This is a multicenter study.
Patients undergo stereotactic radiosurgery on day -7. Patients receive oral temozolomide
once daily on days 1-5 and oral erlotinib hydrochloride once daily on days 1-23. Treatment
with temozolomide and erlotinib hydrochloride repeats every 28 days in the absence of
disease progression or unacceptable toxicity.
Patients undergo cognitive function evaluation as measured by Mini-Mental Status Exam
administration and scoring; quality of life assessment as measured by Functional Assessment
of Cancer Therapy subscale; and physical functioning assessment as measured by Katz index of
activities of daily living and Karnofsky performance status at baseline and then every 8
weeks during study treatment.
Tumor tissue is examined by O6-methylguanine-DNA methyltransferase (MGMT gene) promotor
methylation.
After completion of study therapy, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|